Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02726386 · ClinicalTrials.gov registry record · Phase 2
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
A Phase 2 study of Parkinson's Disease, sponsored by NeuroDerm.
- Active
- Registry status
- Phase 2
- Development phase
- 214
- Enrollment target
- 20
- Study locations
NCT02726386: Active Phase 2 study of Parkinson's Disease, sponsored by NeuroDerm.
NCT02726386 is a Phase 2 study of Parkinson's Disease that is active but no longer recruiting, run by NeuroDerm. The registered enrollment target is 214 participants, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02726386, a Phase 2 study of Parkinson's Disease, is active but no longer recruiting, sponsored by NeuroDerm.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 214 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).
Primary Outcome
Long-term safety (systemic and local) assessment will be based on adverse events (AEs), with a focus on adverse events of special interest (AESI), i.e., infusion site reactions, cases of hypersensitivity, polyneuropathy.
Conditions Studied
Interventions
- DRUG ND0612
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorder Center of Boca Raton - Boca Raton
- MD Clinical - Hallandale
- Infinity Clinical Research, LLC - Hollywood
- University of Florida Health at Jacksonville - Jacksonville
- Neurology Associates, PA - Maitland
- Parkinsons Disease Treatment Center of Southwest Florida - Port Charlotte
- Suncoast Neuroscience Associates - St. Petersburg
- Infinity Clinical Research, LLC - Sunrise
- USF Health Parkinson's Disease and Movement Disorders - Tampa
California
- The Parkinsons and Movement Disorder Institute - Fountain Valley
- Neuro Pain Medical Center - Fresno
Colorado
- University of Colorado Denver - Aurora
- Rocky Mountain Movement Disorders Center - Englewood
Michigan
- QUEST Research Institute - Farmington Hills
- Henry Ford Hospital - West Bloomfield
Arizona
- Xenoscience - Phoenix
Arkansas
- Clinical Trials Inc. - Little Rock
Illinois
- Northwestern University - Chicago
Iowa
- Unity Point Health - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2016-05-04 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What the registry record for NCT02726386 still lists
NCT02726386 is an interventional study that assigns participants to a tested intervention. The registered 214 participants enrollment target is mid-sized for trials with a published cap, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which ND0612 is the first listed.
NCT02726386 names 20 study sites across 9 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02726386 about?
NCT02726386 is a clinical study titled "A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease". This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).
What is the current status of trial NCT02726386?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2016-05-04. Estimated completion is 2027-02.
What conditions does trial NCT02726386 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT02726386?
The interventions under investigation include: ND0612 (DRUG).
Who is sponsoring clinical trial NCT02726386?
This trial is sponsored by NeuroDerm, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02726386 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02726386's enrollment target sits among peer trials
214 31st of 158 higher than 128 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- NCT04421248 · 214 participants · Phase 4
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
- NCT04667520 · 214 participants · NA
Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment
- NCT05418868 · 214 participants · Phase 1
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI